Luke Maese, DO

Journal Article

1. Kamihara J, Fisher L, Schienda J, Vanderwall R, Snir M, Snir G, Simmons E, Khalaj A, Goler E, Hamilton KV, Porter CC, Pencheva B, Schiffman JD, Maese LD, Kohlmann W, Henderson TO, Garber JE, Diller LR, Desai AV, Savage S, Klosky JL, Rana HQ, Mack J (2026). Development and pilot testing of AYA-RISE, a risk information and screening education intervention for adolescents and young adults with cancer risk syndromes. Familial cancer, 25(1), 11.
2. Kang W, Lazo de la Vega L, Comeau H, Agastra E, Maese LD, Kim A, Sukharevsky E, Ceca E, Corson L, White J, Weiser DA, Applebaum MA, Colace SI, Chen M, Johnson JA, Volchenboum S, Pinto NR, Church AJ, Janeway K (2026). Introducing iCatalog as a clinical decision support tool for collaborative pediatric precision oncology studies. Communications medicine, 6(1), 88.
3. Parra Del Riego A, Parker K, Thomsen WC, Ford JB, Heneghan MB, Mangum DS, McNeer JL, Maese LD, Miller CEF, Lemons R, Ghosh (2026). Blinatumomab Utilization in Pediatric B-Cell Acute Lymphoblastic Leukemia: Experience From the Mountain West. Pediatric blood & cancer, e70383.
4. Orgel E, Maese LD, Devidas M, Militano O, Rau RE, Angiolillo A, McNeer J, Schore RJ, Borowitz MJ, Wood BL, Raetz EA, Silverman LB, Winick NJ, Larsen EC, Carroll WL, Winter SS, Dunsmore KP, Hunger SP, Loh M (2026). Toxicity from asparaginase during acute lymphoblastic leukemia induction: A report from the Children's Oncology Group. Blood advances,
5. MacFarland SP, Goodman VE, King-Dowling S, Zelley K, Crompton BD, Schultz KAP, Maese LD, Maxwell KN, Khincha PP, Schwartz L (2026). Liquid Biopsy for Cancer Screening in Li-Fraumeni Syndrome: Interest in Clinical Trial and Reported Barriers to Standard of Care Screening. Cancer prevention research (Philadelphia, Pa.),
6. Spiegel SR, Orr C, Edgar NU, Cahill SR, Le AN, Good M, Lyman J, Feola S, Mehrhoff C, Naumer A, Vagher J, Anez I, Frucht N, Maese LD, Garber JE, Maoz A, Katona BW, MacFarland SP, Maxwell K (2026). Colorectal Neoplasia Rates in Li-Fraumeni Syndrome. The American journal of gastroenterology,
7. Achatz MI, Villani A, Bertuch AA, Bougeard G, Chang VY, Doria AS, Gallinger B, Godley LA, Greer MC, Kamihara J, Khincha PP, Kohlmann WK, Kratz CP, MacFarland SP, Maese LD, Maxwell KN, Mitchell SG, Nakano Y, Pfister SM, Wasserman JD, Woodward ER, Garber JE, Malkin (2025). Update on Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clinical cancer research,
8. Sharma R, Zhang C, Shah R, Frigault MM, Johnson AJ, Mangum DS, Maese LD, Lacayo NJ, Narendran (2025). Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition. Blood neoplasia, 2(4), 100148.
9. Aldoss I, Ali A, Cassaday RD, Curran EK, Luskin MR, Maese LD, Orgel E, Douer (2025). Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations. American journal of hematology,
10. Sleiman MM Jr, Statman MR, Yockel MR, Wu YP, Hamilton JG, Kohlmann WK, Vagher J, Feola S, Maese LD, Chen J, Appel B, Mehrhoff CJ, Peshkin BN, Kadan-Lottick NS, Kupfer GM, Tercyak K (2025). Parental perspectives on the use of tumor molecular profiling and germline genetic testing during their children's cancer treatment. Familial cancer, 24(3), 63.
11. Vagher J, Zakas A, Donovan L, Shoger K, Naumer A, Bly J, Smith-Simmer K, Maese L, Schiffman J, Kohlmann W, Garzon R, Churpek JE, Osman AE (2025). Hematologic Malignancy Frequency, Phenotypes, and Outcomes in Li-Fraumeni Syndrome. JCO precision oncology, 9, e2400860.
12. Fernandes CJ, Du YK, Naumer A, Kagami LA, Le A, Good M, Duvall M, Powers J, Zelley K, Maese LD, MacFarland S, Kohlmann W, Maxwell KN, Katona B (2025). Pancreatic Cancer Risk and Screening Outcomes in Li-Fraumeni Syndrome. Pancreas, 54(7), e618-e623.
13. Mathis CL, Meeks HD, Watt KM, Maese LD, Constance J (2025). Acetaminophen and Acetaminophen-Opioid Combination Prescribing Trends Among Hospitalized Children, Adolescents, and Young Adults with Cancer.
14. Mathis CL, Meeks HD, Watt KM, Maese LD, Constance J (2025). Acetaminophen and Acetaminophen-Opioid Combination Prescribing Trends Among Hospitalized Children, Adolescents, and Young Adults with Cancer. Pharmacological research. Reports, 4,
15. Sharma R (2025). Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition. Blood neoplasia, 2(4),
16. Beigh M, Vagher J, Codden R, Maese LD, Cook S, Gammon (2024). Newborn Screening for Li-Fraumeni Syndrome: Patient Perspectives. Research square,
17. Maese LD, Wlodarski MW, Kim SY, Bertuch AA, Bougeard G, Chang VY, Godley LA, Khincha PP, Kuiper RP, Lesmana H, McGee RB, McReynolds LJ, Meade J, Plon SE, Savage SA, Scollon SR, Scott HS, Walsh MF, Nichols KE, Porter C (2024). Update on Recommendations for Surveillance for Children with Predisposition to Hematopoietic Malignancy. Clinical cancer research,
18. Nakano Y, Kuiper RP, Nichols KE, Porter CC, Lesmana H, Meade J, Kratz CP, Godley LA, Maese LD, Achatz MI, Khincha PP, Savage SA, Doria AS, Greer MC, Chang VY, Wang LL, Plon SE, Walsh M (2024). Update on Recommendations for Cancer Screening and Surveillance in Children with Genomic Instability Disorders. Clinical cancer research, 30(22), 5009-5020.
19. Maese LD, Loh ML, Choi MR, Agarwal S, Aoki E, Liang Y, Lin T, Girgis S, Chen C, Roller SG, Chandrasekaran V, Iannone R, Silverman LB, Raetz EA, Rau R (2024). Recombinant Erwinia Asparaginase (JZP458) in ALL/LBL: Complete Follow-Up of the Children's Oncology Group AALL1931 Study. Blood advances,
20. Maese LD, Loh ML, Choi MR, Lin T, Aoki E, Zanette M, Agarwal S, Iannone R, Silverman JA, Silverman LB, Raetz EA, Rau R (2023). Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study. . Blood, 141(7), 704-712.
21. Fair D, Maese L, Chi YY, Li M, Hawkins DS, Venkatramani R, Rudzinski E, Parham D, Teot L, Malkin D, Plon SE, Li H, Sabo A, Lupo PJ, Schiffman J (2023). TP53 germline pathogenic variant frequency in anaplastic rhabdomyosarcoma: A Children's Oncology Group report. Pediatric blood & cancer, e30413.
22. Foley M, Sharma A, Garfield K, Maese L, Buchmann L, Boyle J, Kohlmann W, Jeter J, Greenberg (2023). A need to tailor surveillance based on family history: describing a highly penetrant familial paraganglioma kindred with an SDHD pathogenic variant. Familial cancer, 22(2), 217-224.
23. Marinoff AE, Spurr LF, Fong C, Li YY, Forrest SJ, Ward A, Doan D, Corson L, Mauguen A, Pinto N, Maese L, Colace S, Macy ME, Kim A, Sabnis AJ, Applebaum MA, Laetsch TW, Glade-Bender J, Weiser DA, Anderson M, Crompton BD, Meyers P, Zehir A, MacConaill L, Lindeman N, Nowak JA, Ladanyi M, Church AJ, Cherniack AD, Shukla N, Janeway K (2023). Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO precision oncology, 7, e2200334.
24. Fan EM*, Vagher J, Meznarich JA, Ubico EM, Goteti S, Peterson D, Rayes A, Maese L (2023). Severe congenital neutropenia, SRP54 pathogenicity, and a framework for surveillance. American journal of medical genetics. Part A, 191(5), 1434-1441.
25. Croci DM, Gamboa NT, Osman AEG, Maese L, Mazur M, Bisson EF, Dailey A (2022). Solitary manifestations of primary B-lymphoblastic lymphoma of the spine: Systematic literature review with case illustration. Clinical neurology and neurosurgery, 212, 107064.
26. Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, Whipple NS, Sabnis AJ, Foster JH, Shusterman S, Yoon J, Weiss BD, Abdelbaki MS, Armstrong AE, Cash T, Pratilas CA, Corradini N, Marshall LV, Farid-Kapadia M, Chohan S, Devlin C, Meneses-Lorente G, Cardenas A, Hutchinson KE, Bergthold G, Caron H, Chow Maneval E, Gajjar A, Fox (2022). Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1 or ALK aberrations (STARTRK-NG). Neuro-oncology, 24(10), 1776-1789.
27. MacFarland SP, Maese L, Rednam SP, Kamihara J, Perrino MR, Nichols KE, Brodeur GM, Schiffman JD, Plon SE, Diller LR, Malkin D, Porter CC, Villani (2022). Collaboration to Promote Research and Improve Clinical Care in the Evolving Field of Childhood Cancer Predisposition. Cancer prevention research (Philadelphia, Pa.), 15(10), OF1-OF7.
28. Church AJ, Corson LB, Kao PC, Imamovic-Tuco A, Reidy D, Doan D, Kang W, Pinto N, Maese L, Laetsch TW, Kim A, Colace SI, Macy ME, Applebaum MA, Bagatell R, Sabnis AJ, Weiser DA, Glade-Bender JL, Homans AC, Hipps J, Harris H, Manning D, Al-Ibraheemi A, Li Y, Gupta H, Cherniack AD, Lo YC, Strand GR, Lee LA, Pinches RS, Lazo De La Vega L, Harden MV, Lennon NJ, Choi S, Comeau H, Harris MH, Forrest SJ, Clinton CM, Crompton BD, Kamihara J, MacConaill LE, Volchenboum SL, Lindeman NI, Van Allen E, DuBois SG, London WB, Janeway K (2022). Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nature medicine, 28(8), 1581-1589.
29. Lazo De La Vega L, Comeau H, Sallan S, Al-Ibraheemi A, Gupta H, Li YY, Tsai HK, Kang W, Ward A, Church AJ, Kim A, Pinto NR, Macy ME, Maese LD, Sabnis AJ, Cherniack AD, Lindeman NI, Anderson ME, Cooney TM, Yeo KK, Reaman GH, DuBois SG, Collins NB, Johnson BE, Janeway KA, Forrest S (2022). Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. JCO precision oncology, 6, e2200390.
30. Maxwell K.N (2022). Inherited TP53 Variants and Risk of Prostate Cancer. European urology, 81(3), 243-250.
31. Maxwell KN, Cheng HH, Powers J, Gulati R, Ledet EM, Morrison C, Le A, Hausler R, Stopfer J, Hyman S, Kohlmann W, Naumer A, Vagher J, Greenberg SE, Naylor L, Laurino M, Konnick EQ, Shirts BH, AlDubayan SH, Van Allen EM, Nguyen B, Vijai J, Abida W, Carlo MI, Dubard-Gault M, Lee DJ, Maese LD, Mandelker D, Montgomery B, Morris MJ, Nicolosi P, Nussbaum RL, Schwartz LE, Stadler Z, Garber JE, Offit K, Schiffman JD, Nelson PS, Sartor O, Walsh MF, Pritchard C (2021). Inherited TP53 Variants and Risk of Prostate Cancer. European urology,
32. Iglesias Cardenas F, Agarwal AM, Vagher J, Maese L, Fluchel M, Afify (2021). Two Clonally Distinct B-Cell Lymphomas Reveal the Diagnosis of XLP1 in a Male Child and His Asymptomatic Male Relatives: Case Report and Review of the Literature. Journal of pediatric hematology/oncology, 43(8), e1210-e1213.
33. Lozano-Chinga M*, Draper L, George TI, Agarwal AM, Dansie DM, Maese (2021). Bone marrow necrosis in pediatric malignancies: 10-Year retrospective review and review of literature. Pediatric blood & cancer, 68(3), e28806.
34. Maese L, Rizzari C, Coleman R, Power A, van der Sluis I, Rau R (2021). Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?. Pediatric blood & cancer, 68(10), e29169.
35. Rower JE, King AD, Wilkins D, Wilkes J, Yellepeddi V, Maese L, Lemons RS, Constance J (2021). Dronabinol Prescribing and Exposure Among Children and Young Adults Diagnosed with Cancer. Journal of adolescent and young adult oncology, 10(2), 175-184.
36. Olson J, Mehra S, Hersh AL, Thorell EA, Stoddard GJ, Maese L, Barnette PE, Lemons RS, Pavia AT, Knackstedt E (2021). Oral Step-Down Therapy With Levofloxacin for Febrile Neutropenia in Children With Cancer. Journal of the Pediatric Infectious Diseases Society, 10(1), 27-33.
37. Bender C, Maese L, Carter-Febres M, Verma (2021). Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review. Blood and lymphatic cancer, 11, 25-40.
38. Mangum DS, Meyer JA, Mason CC, Shams S, Maese LD, Gardiner JD, Downie JM, Pei D, Cheng C, Gleason A, Luo M, Pui CH, Aplenc R, Hunger SP, Loh M, Greaves M, Trede N, Raetz E, Frazer JK, Mullighan CG, Engel ME, Miles RR, Rabin KR, Schiffman J (2021). Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia. JAMA oncology, 7(10), 1521-1528.
39. Kim J, Light N, Subasri V, Young EL, Wegman-Ostrosky T, Barkauskas DA, Hall D, Lupo PJ, Patidar R, Maese LD, Jones K, Wang M, Tavtigian SV, Wu D, Shlien A, Telfer F, Goldenberg A, Skapek SX, Wei JS, Wen X, Catchpoole D, Hawkins DS, Schiffman JD, Khan J, Malkin D, Stewart D (2021). Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma. JCO precision oncology, 5,
40. Schienda J, Church AJ, Corson LB, Decker B, Clinton CM, Manning DK, Imamovic-Tuco A, Reidy D, Strand GR, Applebaum MA, Bagatell R, DuBois SG, Glade-Bender JL, Kang W, Kim A, Laetsch TW, Macy ME, Maese L, Pinto N, Sabnis AJ, Schiffman JD, Colace SI, Volchenboum SL, Weiser DA, Nowak JA, Lindeman NI, Janeway KA, Crompton BD, Kamihara (2021). Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO precision oncology, 5,
41. Kerrigan K (2021). Lung cancer in li-fraumeni syndrome. JCO precision oncology, 5, 552-556.
42. Kim J (2021). Pathogenic germline variants in cancer susceptibility genes in children and young adults with rhabdomyosarcoma. JCO precision oncology, 5, 75-87.
43. Thomsen W (2021). Early presentation of homozygous mismatch repair deficient glioblastoma in teen with lynch syndrome: Implications for treatment and surveillance. JCO precision oncology, 5, 670-675.
44. Hecht A, Meyer JA, Behnert A, Wong E, Chehab F, Olshen A, Hechmer A, Aftandilian C, Bhat R, Choi SW, Chonat S, Farrar JE, Fluchel M, Frangoul H, Han JH, Kolb EA, Kuo DJ, MacMillan ML, Maese L, Maloney KW, Narendran A, Oshrine B, Schultz KR, Sulis ML, Van Mater D, Tasian SK, Hofmann WK, Loh ML, Stieglitz (2020). Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. Haematologica, Online ahead of print, 178-186.
45. Brown P, Inaba H, Annesley C, Beck J, Colace S, Dallas M, DeSantes K, Kelly K, Kitko C, Lacayo N, Larrier N, Maese L, Mahadeo K, Nanda R, Nardi V, Rodriguez V, Rossoff J, Schuettpelz L, Silverman L, Sun J, Sun W, Teachey D, Wong V, Yanik G, Johnson-Chilla A, Ogba (2020). Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 18(1), 81-112.
46. Hendrickson PG, Luo Y, Kohlmann W, Schiffman J, Maese L, Bishop AJ, Lloyd S, Kokeny KE, Hitchcock YJ, Poppe MM, Gaffney DK, Tao (2020). Radiation therapy and secondary malignancy in Li-Fraumeni syndrome: A hereditary cancer registry study. Cancer medicine, 9(21), 7954-7963.
47. Donovan L.N (2020). Germ cell mosaicism: A rare cause of Li-Fraumeni recurrence among siblings. JCO precision oncology, 4, 662-664.
48. Hamilton KV, Maese L, Marron JM, Pulsipher MA, Porter CC, Nichols K (2019). Stopping Leukemia in Its Tracks: Should Preemptive Hematopoietic Stem-Cell Transplantation be Offered to Patients at Increased Genetic Risk for Acute Myeloid Leukemia?. Journal of clinical oncology, 37(24), 2098-2104.
49. Maese L, Raetz E (2019). Can Ph-like ALL be effectively targeted?. Best practice & research. Clinical haematology, 32(4), 101096.
50. Tak CR, Biltaji E, Kohlmann W, Maese L, Hainaut P, Villani A, Malkin D, Sherwin CMT, Brixner DI, Schiffman J (2019). Cost-effectiveness of early cancer surveillance for patients with Li-Fraumeni syndrome. Pediatric blood & cancer, 66(5), e27629.
51. Maese L, Li KD, Xu X, Afify Z, Paxton CN, Putnam (2017). Acute Leukemia and Concurrent Mediastinal Germ Cell Tumor: Case Report and Literature Review. Fetal and pediatric pathology, 36(2), 168-176.

Review

1. Vagher J, Mehrhoff CJ*, Florou V, Maese L (2024). Genetic Predisposition to Sarcoma: What Should Clinicians Know?. Current treatment options in oncology, 25(6), 769-783.
2. Maese LD, Pulsipher M (2023). Blinatumomab Conundrum in Low-Risk Relapsed B-Cell ALL. Journal of clinical oncology, 41(25), 4087-4092.
3. Maese L, Rau R (2022). Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. Frontiers in pediatrics, 10, 902117.
4. Vagher J,Dietz MS,Schiffman JD,Kohlmann W,Maese (2022). Germline predisposition to soft tissue sarcoma. Journal of cancer metastasis and treatment, 8,
5. Maese L (2022). Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. Frontiers in pediatrics, 10,

Book Chapter

1. Hogan L.E (2022). Treatment of Pediatric B- and T-Cell Acute Lymphoblastic Leukemia. Clinical Management of Acute Lymphoblastic Leukemia from Bench to Bedside, 75-104.
2. Vagher J (2021). Inherited risk for childhood leukemia. Hereditary Basis of Childhood Cancer, 315-360.
3. Greenberg S.E (2020). Von Hippel-Lindau syndrome. JCO precision oncology, 1005-1020.

Letter

1. Tantravahi SK, Huber BD, Vagher J, Maese L, Pomicter AD, Al-Sweel N, Asch JD, Toydemir RM, Hong B, Parker (2022). Genome-wide uniparental disomy as a mechanism of immune escape in acquired aplastic anaemia. British journal of haematology, 198(6), e78-e81.

Huntsman Cancer Institute News

• AI-Powered “Lab-on-a-Chip” Platform May Enable Same-Day Treatment Decisions for Pediatric Patients